HDAC9 and osteosarcoma: A genome wide loss of function screen identified HR23B expression as a determinant of sensitivity to HDAC inhibitor induced apoptosis in an osteosarcoma cell line, and it is therefore a potential biomarker of HDAC inhibitor sensitivity [17].